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Abstract
Here we presented that the expression of RUNX3 was significantly decreased in 75 cases of clear cell renal cell carcinoma
(CCRCC) tissues (p,0.05). Enforced RUNX3 expression mediated 786-O cells to exhibit inhibition of growth, G1 cell-cycle
arrest and metastasis in vitro, and to lost tumorigenicity in nude mouse model in vivo. RUNX3-induced growth suppression
was found partially to regulate various proteins, including inhibition of cyclinD1, cyclinE, cdk2, cdk4 and p-Rb, but increase
of p27
Kip1, Rb and TIMP-1. Therefore, RUNX3 had the function of inhibiting the proliferative and metastatic abilities of
CCRCC cells by regulating cyclins and TIMP1.
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Introduction
Renal cell carcinoma (RCC), the relatively uncommon
malignant disease with a dismal outcome arising from the adult
kidney, afflicts about 150,000 people globally and accounts for
nearly 78,000 deaths each year [1]. Clear cell (75–80%), and
papillary (10–15%) carcinoma are the two most frequent subtypes
of RCC [2]. By now, the etiology and pathogenesis of renal cancer
remain unclear, although heterogeneous genetic alterations have
been reported, as VHL, which have been found to be inactivated
in the 70% to 80% of CCRCC. More great efforts are needed to
identify the signature gene, which will provide a conceptual
framework for its early detection and effective treatment.
Runt domain family, which contains RUNX1, RUNX2, and
RUNX3, are main regulators of gene expression in cell
proliferation and differentiation in human. The human RUNX
genes encode the a subunit of the Runt-domain transcription
factor PEBP2/CBF [3,4]. Previous report indicated a direct
correlation with reduced expression of RUNX3 and development
and progression of various human cancers such as in gastric and
colon tumor [3,4,5,6]. However, whether and how RUNX3
functions in human CCRCC remains unknown.
In the present study, we investigated the expression and
molecular function of RUNX3 in human CCRCC tissues and
cells. Our results showed for the first time that restoration of
RUNX3 expression directly attenuated the tumorigeneicity and
metastasis of CCRCC. Moreover, RUNX3 positively regulates
several cell cycle molecules and TIMP-1 of human CCRCC
cells.
Materials and Methods
Tissue collection and immunohistochemistry
Immunohistochemistry was performed by using the Histostain
TM-Plus SP kit [7]. 75 formalin fixed paraffin-embedded
specimens of primary CCRCC and the matched adjacent
noncancerous tissues were obtained from the Department of
pathology in our hospital. Six resected fresh CCRCC and adjacent
non-tumorous specimens were collected in the Department of
Urology in our hospital and were immediately frozen in liquid
nitrogen and kept at 70uC until the extraction of lysate. All
samples were obtained from patients who gave informed consent
to use excess specimens for research purposes. The use of human
tissues in this study was approved by the institutional review board
of the Fourth Military Medical University and was done in
accordance with international guidelines for the use of human
tissues. Immunohistochemistry was done as described using a
rabbit polyclonal antibody against human RUNX3 at a dilution of
1:200 (Active Motif, Carlsbad, CA) [7]. Negative control was
performed by replacing the primary antibody with pre-immune
mouse serum. All sections were examined and scored indepen-
dently by two investigators without the knowledge of patients’
outcome.
Expression of RUNX3 was evaluated according to the ratio of
positive cells per specimen and staining intensity as described
previously [8]. The ratio of positive cells per specimen was
evaluated quantitatively and scored as follows: 0=staining of V
1%; 1=staining of 2% to 25%; 2=staining of 26% to 50%;
3=staining of 51% to 75%; and 4=staining of . 75% of the cells
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32961examined. Intensity was graded as follows: 0=negative; 1=weak;
2=moderate; and 3=strong. A total score of 0 to 12 was finally
calculated and graded as negative (2; score: 0–1), weak (+; score:
2–4), moderate (++; score: 5–8), and strong (+++; score: 9–12).
Cell culture
Human CCRCC-derived cell lines 786-O, A-498, and human
kidney proximal tubular cell lines HKC, HK-2, were cultured with
RPMI1640 (HyClone) or DMEM (Gibco) supplemented with 10%
fetal-calf-serum, penicillin (100 U/ml), and streptomycin (100 mg/
ml), in a CO2 incubator (Forma Scientific) [9,10].
Plasmid construction and cell transfection
PSilencer3.1 (Ambion) was used for construction of human
RUNX3-siRNA vectors according to manufacturer’s protocol.
The specific oligonucleotides RUNX3-F: 5-GATCCTGACGA-
GAACTACTCCGCTTTCAAGAGAAGCGGAGTAGTTCTC-
GTCATTTTTTGGAAA-3, RUNX3-2R: 5-AGCTTTTCCAA-
AAAATGACGAGAACTACTCCGCTTCTCTTGAAAGCGG-
AGTAGTTCTCGTCA G-3 were annealed and then subcloned
into the BamHI/HindIII cloning site of pSilencer3.1 respectively.
Full-length human RUNX3 vector (pBK-RUNX3) and the
control vector were gifts of professors Prof. Paul J Farrell from
Department of Virology, Ludwig Institute for Cancer Research,
UK. Cell transfection was performed with Lipofectamine2000
(Invitrogen, Carlsbad, CA) as described in manufacturer’s protocol
in our previous work [11,12]. Briefly, cells were plated and grown
to 70–90% confluence without antibiotics and then transfected
with 1 mg plasmids. For stable transfecion, G418 (400 mg/ml) was
added into cells after 24 h of transfection. For transient
transfection, cells were harvested for further experiments after
48 h of transfection. Mixed clones were screened and expanded
for an additional 6 weeks. So the transfected cell lines were
designated as 786-O-RUNX3, 786-O-Ctrl, HKC-siRUNX3, and
HKC-Ctrl respectively.
RNA extraction and real-time RT-PCR
Real-time RT-PCR was performed to determine the expression
levels of target genes RUNX3. Total RNA was extracted from
cultured cells using TRIZOL reagent (Invitrogen Life Technolo-
gies). cDNA (accession number HGNC:10473 ) was generated by
using a TaqMan Reverse Transcription Kit (Applied Biosystems).
Real-time PCR analyses were performed with a TaqMan RNA
Assay kit (Applied Biosystems). Primer of RUNX3 sequence was
designed using Primer Express Software (Version 1.5). The
primer-RUNX3 sequence: (Forward) 59-GACTGTGATGGCA-
GGCAATGA-39 and (Reverse) 59-CGAAGCGAAGGTCGTT-
GAA-39. All protocols and data collection were performed on an
iCycler (Bio-Rad) according to the manufacturer’s instructions.
Each sample was run in triplicate for the target gene and the
internal control gene.
MTT Assay
Cells were cultured on 96-well plates (Corning) at 1610
4 cells/
well. Viable cells were assayed at 1, 2, 3, 4, 5, and 6 days.
Following MTT (Sigma) incubation, the cells were lysed in 150 ml
of 100% DMSO and the absorbance was tested at 490 nm using
the 96-well plate reader (Dynex Technologies) [13]. Each
experiment was performed in triplicate.
Soft agar assay
Soft agar assay was determined as described previously [7,14,15,16].
Briefly, a volume of 2 ml of 0.5% agar was added to each well of 12-
well plate. Cells were detached and mixed with the topagarose
suspension at a final concentration of 0.3%, which was then layered
o n t ot h e0 . 5 %a g a r o s eu n d e r l a y .T h en u m b e ro ff o c i.100 mmw a s
counted after 17 days. Each experiment was performed in triplicate.
Cell cycle analysis
Flow cytometry analysis was performed as described [17]. The
transfected cells were harversted when they were 70-80%
confluent, suspended in 0.5 ml of 70% alcohol and kept at 4uC
overnight. The DNA content of stained nuclei was analyzed by a
flow cytometer (EPICS XL, Coulter, Miami FL). The cell cycle
was analyzed using Multicycle-DNA Cell Cycle Analyzed
Software. Each experiment was done in triplicate.
Cell migration assays
The ability of 786-O-Ctrl and 786-O-RUNX3 cells to migrate
was detected using Transwells (8-mm pore size, Corning Costar
Corp). The Transwells were put into the 24-well plates. Freshly
trypsinized and washed cells were suspended in DMEM containing
1% fetal bovine serum. 5610
4 cells/well were placed in the top
chamber of each insert (BD Biosciences, NJ), with the non-coated
membrane. 500 ml of DMEM containing 10% fetal bovine serum
was added into the lower chambers. After incubating for 24 h at
37uC in a 5% CO2 humidified incubator, cells were fixed with 95%
absolute alcohol and stained with crystal violet. The cells in the
inner chamber were removed with a cotton swab and the cells
attached to the bottom side of the membrane were counted and
imaged under an inverted microscope (Olympus Corp. Tokyo,
Japan) at 6200 magnification over ten random fields in each well.
Each experiment was performed in triplicate [18].
Tumorigenicity
Tumorigenicity in Nude Mice was determined as described
previously [7,15]. Two groups of 6 mice each were injected
subcutaneously with transfected cells at a single site. Tumor onset
was scored visually and by palpitation at the site of injection by two
trained laboratory staffs at different times on the same day. Average
tumor size was estimated by physical measurement of the excised
tumor at the time of sacrifice. Animals were sacrificed 28 days after
injection. These tumors were weighed and verified by hematoxylin
and eosin (H&E) staining. Nude mice were manipulated and cared
for according to NIH Animal Care and Use Committee guidelines
in the Experiment Animal Center of the Fourth Military Medical
University (Xi’an, Shanxi, Province, P.R. China).
Western blot analysis
Protein extraction and immunoblot analyses were performed as
described [7,15,18]. Cell or tissues lysate were respectively
separated by SDS-polyacrylamide gel electrophoresis, blotted onto
nitrocellulose membrane, and incubated with a primary antibody,
including monoclonal antibodies against RUNX3 (Active Motif,
Carlsbad, CA), cyclin D1, cyclin E, TIMP-1, TIMP-2, MMP2,
MMP9, Tubulin (Santa Cruz Biotech); b-actin (Sigma); cdk2,
cdk4, p27
Kip1 (BD Biosciences); Rb and pRb (Cell Signaling
Technology). After washing, the membrances were incubated with
the HRP-conjugated goat anti-mouse or anti-rabbit IgG antibody
(Wuhan, Hubei, China) for 2 h at room temperature. Blots were
visualized by using the ECL system (Amersham Pharmacia
Biotech). Each assay was repeated at least thrice.
Statistical analysis
The difference between each group was analyzed by Kruskal-
Wallis rank test, Student’s test or Mann-Whitney U test using
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were considered statistically different at P,0.05.
Results
RUNX3 expression was loss or decreased in CCRCC
tissues and the derived cell lines
The expression of RUNX3 was assessed by immunohistochem-
istry in CCRCC samples with the matched adjacent noncancerous
tissues. It was found that RUNX3 was predominantly located in
the cytoplasm and nucleus of kidney proximal tubular cells in
noncancerous tissues (Fig. 1a). As shown in Table 1, 11 (14.66%),
5 (6.67%), 10 (13.33%) and 49 (65.33%) of the adjacent
noncancerous tissues samples had negative, weak, moderate, and
strong RUNX3 immunostaining, respectively. On the contrary, 52
(69.33%), 6 (8%), 6 (8%) and 11 (14.67%) of the renal tumor
tissues specimens of CCRCC had negative, weak, moderate, and
strong RUNX3 immunostaining, respectively (Fig. 1b). The
average RUNX3 staining score in adjacent noncancerous tissues
of CCRCC was significantly higher than CCRCC (0.853 versus
0.306, P,0.05). To provide causal evidence of the role of RUNX3
in CCRCC development and progression, we first determined
RUNX3 expression in six human CCRCC tissues and two derived
cell lines in mRNA and protein levels, compared with the matched
adjacent noncancerous tissues and the human normal kidney
proximal tubular cell lines. As shown in Fig. 1c, Runx3 was
significantly lower expressed in CCRCC tissues compared with
matched adjacent noncancerous tissues. As shown in Fig. 1d and
1e, 786-O and A-498, had a loss or drastic decrease of RUNX3
expression, as compared with their matched the HKC and HK-2
in mRNA and protein levels.
RUNX3 repressed the growth and metastasis of CCRCC
cells in vitro
PBK-RUNX3 vector was used to up-regulate the expression of
RUNX3 in 786-O cells, and the control cells were transfected with
the control vector pBK-CMV [11,12]. After cell transfection and
antibiotic screening for 6 weeks, the expression of RUNX3 in stably
transfectedcells and the controlcells pBK-CMVwasdetermined by
Western blot. RUNX3 could be significantly up-regulated in 786-
O-RUNX3 cells, compared with the control cells 786-O-Ctrl
(Fig. 2a). To determine the impact of this restored RUNX3
expression on the growth and metastasisofhumanCCRCC derived
cell lines 786-O, first we determined viable cells and the growth
curve using an MTT assay. Restored RUNX3 expression in 786-O
cells clearly inhibited the growth of 786-O-RUNX3 cells in vitro
(Fig. 2b, P , 0.05), showing that RUNX3 has a tumor-suppressive
function in human CCRCC cells. We next studied the ability of
these 2 transfected cell lines to form colonies on 6-well cell culture
plates for 3 weeks. 786-O-RUNX3 cells have reduced colony
formation as low as 2 mM. The number of colonies formed was
reduced to 18.661.5 compare to 4.861.1. Colony formation
analysis showed that compared with the control cells, 786-O-
RUNX3 transfected cells 786-O-RUNX3 transfected tumor cells
have a greatly reduced capacity to form colonies (Fig. 2c, P , 0.05).
Because migratory potential is a common feature in the process of
tumor metastasis, we then studied the influence of RUNX3 on the
migratory abilities of CCRCC cells in vitro by Transwell assay. As
shown in Fig. 2d, 786-O-RUNX3 cells and the control ones were
through Matrigel on Boyden chamber assay, with average cell
numbers of 13.6+4.25 and 55.467.62, respectively (P,0.05). All
these suggested that RUNX3 could inhibit the growth and
metastatic abilities of CCRCC cells in vitro.
Figure 1. RUNX3 protein expression in CCRCC tissues and the matched noncancerous counterparts. a and b. Representative
immunohistochemical photographs were taken at different magnifications in CCRCC tumor tissues and their matched noncancerous counterparts
(6100 a1, 6200 a2, 6400 a3 and negative control a4 for noncancerous tissues; 6100 b1, 6200 b2, 6400 b3 and negative control b4 for tumor
tissues). c. Expression protein levels of Runx3 in six CCRCC and the matched adjacent noncancerous tissues. d.Expression mRNA levels of RUNX3 in
the CCRCC-derived cell lines and human kidney proximal tubular cell lines by real time RT-PCR. 18S was used as an internal control.
*P ,0.05 vs HKC
cells. e. Expression protein levels of RUNX3 in the CCRCC-derived cell lines and human kidney proximal tubular cell lines by Western Blot. Tubulin was
used as an internal control.
doi:10.1371/journal.pone.0032961.g001
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vivo
Ectopic expression of RUNX3 protein repressed the tumorige-
nicity of CCRCC cells by nude mice in vivo. As shown in Fig 3a,b,
in vivo subcutaneous tumor formative assay was adopted to
examine the proliferative ability of 786-O-RUNX3 in nude mice.
Compared with the control 786-O-Ctrl cells, injection of 786-O-
RUNX3 cells led to dramatically decreased tumor weight (Fig. 3a,
P,0.05) and tumor size (Fig. 3b, P,0.05). So the in vivo assay
suggested that RUNX3 had a potential to inhibit tumorigenicity of
CCRCC cells.
RUNX3 suppressed cell cycle progression of CCRCC cells
by targeting cell cycle related molecules
Our data by flow cytometry analysis showed that the cell cycle
distribution of 786-O cells was significantly affected by ectopic
expression of RUNX3 (Fig. 3c). The cell cycle profile indicates that
70.3% of the 786-O-RUNX3 cells were arrested at G1/S phase,
whereas only 55.7% 786-O-Ctrl cells respectively were arrested at
the G1/S phase. No significant differences were observed in the
fraction of cells in G2 phase. Hence, it indicated that RUNX3
exerted an inhibitory effect on cell cycle progression and this might
partly explain the growth suppression effect of RUNX3 on
CCRCC cells.
In order to explore the underlying molecular mechanism of
RUNX3 inducing cell cycle arrest, we detected the expression of
cell cycle-related molecules. Our results indicated that ectopic
expression of RUNX3 was associated with the reduction of cyclin
D1/cdk4, cyclin E/cdk2 and p-Rb but with the increase of p27,
Rb protein expression (Fig. 4a). The results were inversed by
down-regulating RUNX3 with specific siRNA in HKC cells
(Fig. 4b). Therefore, we might infer that RUNX3 induced growth
suppression of renal cancer cells partially by regulating various
proteins which were controlling G1 to S progression.
RUNX3 abrogated metastasis of CCRCC by targeting
TIMP1
To study the possible role of MMPs in RUNX3-induced
inhibition of cell metastasis, ECM degradation is an essential step
in tumor invasion and metastasis, which was mainly mediated by
the balance between some matrix metalloproteinases (MMPs),
such as MMP2 and MMP9 [13,14] and tissue inhibitors of matrix
Figure 2. Effects of RUNX3 on the abilities of growth and metastasis in vitro. a. After infection, the expression of RUNX3 in 786-O-Ctrl and
786-O-RUNX3 was evaluated by Western blot. Tubulin was used as an internal control. b. Effect of RUNX3 in regulating 786-O cells proliferation.
Monolayer growth rates of 786-O, 786-O-Ctrl and 786-O-RUNX3 cells were determined by MTT assays. Values represent the mean (SEM) from at least
three separate experiments.
*P ,0.05 vs 786-O cells. c. Effect of RUNX3 on colony formation of 786-O cells. Cells were placed in media containing soft
agar and incubated for 17 days. The number of foci .100 mm was counted. Values represent the mean (SEM) from at least three separate
experiments, each conducted in triplicate.
*P ,0.05 vs 786-O-Ctrl cells. d. Cell migration assays. Representative fields of migration cells on the
membrane (magnification of6200). Average migration cell number per field. The migration cell number of 786-O-RUNX3 is drastically decreased than
that transfected with negative control.
*P,0.05 vs 786-O-Ctrl cells, Student’s T-test, n=10.
doi:10.1371/journal.pone.0032961.g002
Table 1. Clinicopathological associations of RUNX3 expression in patients with CCRCC.
RUNX3 Expression Level P value
2 ++ +
Adjacent tissue of CCRCC 12/77(15.58%) 16/77(20.78%) 49/77 (63.64%)
CCRCC tissues 52/75(69.33%) 12/75(16%) 11/75(14.67%) ,0.001
**
Note: Interpretation of Runx3 staining was described in Section 2. Runx3 staining was graded as negative (2; score: 0–1), weak (+; score:2–4), and strong (++; score:5–8).
Pearson’s X
2 Test,
**P,0.001 vs non-cancerous tissues.
doi:10.1371/journal.pone.0032961.t001
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So we examined the effect of RUNX3 on the expressions of
MMP2, MMP9, TIMP1, TIMP2 in CCRCC cells after
transfection in 786-O and HKC. Our data confirmed that the
expression of TIMP1 could be significantly up-regulated in 786-O-
RUNX3 cells (Fig. 4a) and down-regulated in HKC-siRUNX3
cells in protein levels (Fig. 4b). However, the protein expression
levels of MMP2, MMP9 and TIMP2 were not changed in 786-O-
RUNX3 and HKC-siRUNX3 cells. Taken together, we suggested
that inhibiting effect of RUNX3 on metastasis of CCRCC was at
least partially mediated by ectopic expression of TIMP-1, which
possibly caused the consequent degradation of ECM.
Discussion
RUNX3, is likely a significant candidate several tumor
suppressor gene previously. Our study also provided direct
evidence that RUNX3 functions as a tumor suppressor in human
renal cancer. Therefore, a better understanding of the molecular
basis for the molecular function of the aberrant RUNX3 signaling
pathway may help in designing effective therapies to control
CCRCC growth and metastasis [19].
In addition, classification into gene ontology categories
according to involvement in different biological processes showed
that several genes involved in metastasis and cell cycle were
changed by RUNX3 [20]. It is interesting to examine the
correlation between RUNX3 and these molecules. Because
RUNX3 has the potential role in TGF-b signaling, and TGF-b
generally induces cell cycle arrest at the G0/G1 phase by
increasing the expression or activity of specific cyclin-dependent
kinase inhibitors [21,22,23] and many other potential targets [24],
the tumor suppressor activity of RUNX3 may be realized by
inducing cell cycle arrest [25,26]. Beyond mid-G1, near the end of
the G1/S restriction point, the expression of cyclin E with cdk2
has been shown to promote the phosphorylation of Rb [27]. P27 is
an important cell cycle inhibitors of the Cyclin D1/cdk4
complexes, cyclin E/cdk2 complexed, exerts its inhibitory activity
on many steps of the cell cycle [28]. All these molecules are
actually involved in the regulation of cell cycle arrest by RUNX3 is
currently under investigation in present work [19]. Our prolifer-
Figure 3. Effect of RUNX3 on tumorigenicity in nude mice and
the cell-cycle analysis of 786-O cells. a. Average tumor weight was
measurement of the excised tumors at the time of sacrifice.
*P ,0.05 vs
786-O-Ctrl cells. b. Average tumor size was estimated by physical
measurement of the excised tumor at different time.
*P ,0.05 vs 786-O-
Ctrl cells. d. 786-O-Ctrl cells and 786-O-RUNX3 cells were cultured in
DMEM for 24 h. Cells were harvested and processed for FACS analysis.
doi:10.1371/journal.pone.0032961.g003
Figure 4. Target genes regulated by RUNX3. a. The expression of
cyclin D1, cyclin E, cdk2, cdk4, p-Rb, Rb, p27, MMP2, MMP9, TIMP-1 and
TIMP-2 proteins were evaluated in 786-O-Ctrl and 786-O-RUNX3 cells by
Western blot. b. The expression of cyclin D1, cyclin E, cdk2, cdk4, p-Rb,
Rb, p27, MMP2, MMP9, TIMP-1 and TIMP-2 proteins were evaluated in
HKC-Ctrl and HKC-siRUNX3 by Western blot. All examined gene
expression levels quantitatively analyzed and expressed as the ratios
over b-actin.
doi:10.1371/journal.pone.0032961.g004
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cancer cell growth by inducing G1/S arrest. Then we tested the
expression of cell cycle related molecules in the parent cells and the
transfected cells, such as the classic cell cycle regulator Cyclins, cdk
and cdk inhibitor molecules. In all, results obtained in the present
study provided that RUNX3 exerted its effects on cell cycle
progression mainly via inhibiting of Cyclin D1/cdk4 and cyclin E/
cdk2 complexes, ectopic expression ofp27
Kip1 expression and
accelerating of pRb dephosphorylation.
Metastasis is also a mortal factor for cancer patients. By now,
the exact metastatic mechanisms of CCRCC are still not fully
elucidated. In previous studies, evidence has been accumulated
that metastasis of solid tumors require the action of tumor-
associated proteases, which promote the dissolution of the
surrounding tumor matrix and the basement membrane [29,30].
As we know, MMPs and their tissue inhibitors, TIMPs played an
important role in that process in tumor metastasis [30,31]. In this
study, we observed the relationship of RUNX3 with them. Our
study suggested that in CCRCC cells the expression of MMP2,
MMP9 and TIMP2 may not be regulated by RUNX3. But
RUNX3 could significantly change the expression of TIMP1
levels. All these improved that RUNX3 may be involved in other
unidentified mechanisms, such as TIMP1, thereby degrading
extracellular matrix and participating in the metastasis of
CCRCC.
In all, experimental evidence confirmed that RUNX3 was
down-regulated in CCRCC and appeared to be a potent growth
and metastasis inhibitor in renal cancer cells. Despite our work
suggested that the role of RUNX3 as tumor suppressor might be
played through the cell cycle related proteins and TIMP-1, more
precise mechanism remained to be elucidated deeply.
Acknowledgments
We are grateful to Prof. Paul J. Farrell from Department of Virology,
Ludwig Institute for Cancer Research, UK, for the full-length human
RUNX3 vector (pBK-RUNX3).We are grateful to Yongzhan Nie and Xin
Wang for excellent guidance during the experiment.
Author Contributions
Conceived and designed the experiments: LH DF SS CG XZ. Performed
the experiments: LH PZ HW WL CH XZ XL. Analyzed the data: LH XZ.
Contributed reagents/materials/analysis tools: LH CH FY YC XZ. Wrote
the manuscript: LH XZ.
References
1. Zbar B, Klausner R, Linehan WM (2003) Studying cancer families to identify
kidney cancer genes. Annu Rev Med 54: 217–233.
2. Ibanez DCI, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, et al. (2006)
Identification of novel target genes by an epigenetic reactivation screen of renal
cancer. Cancer Res 66: 5021–5028.
3. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, et al. (2002) Causal
relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:
113–124.
4. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, et al. (2005) RUNX3, a novel
tumor suppressor, is frequently inactivated in gastric cancer by protein
mislocalization. Cancer Res 65: 7743–7750.
5. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, et al. (2005) RUNX3 inactivation by
point mutations and aberrant DNA methylation in bladder tumors. Cancer Res
65: 9347–9354.
6. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, et al. (2004) Promoter
hypermethylation downregulates RUNX3 gene expression in colorectal cancer
cell lines. Oncogene 23: 6736–6742.
7. Meng Y, He L, Guo X, Tang S, Zhao X, et al. (2010) Gankyrin promotes the
proliferation of human pancreatic cancer. Cancer Lett 297: 9–17.
8. Wang J, Wu K, Zhang D, Tang H, Xie H, et al. (2005) Expressions and clinical
significances of angiopoietin-1, -2 and Tie2 in human gastric cancer. Biochem
Biophys Res Commun 337: 386–393.
9. Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, et al. (1994) HK-2:
an immortalized proximal tubule epithelial cell line from normal adult human
kidney. Kidney Int 45: 48–57.
10. Tan XY, Zheng FL, Zhou QG, Duan L, Li Y (2005) [Effect of bone
morphogenetic protein-7 on monocyte chemoattractant protein-1 induced
epithelial-myofibroblast transition and TGF-beta1-Smad 3 signaling pathway
of HKC cells]. Zhonghua Yi Xue Za Zhi 85: 2607–2612.
11. Guo C, Ding J, Yao L, Sun L, Lin T, et al. (2005) Tumor suppressor gene
Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregu-
lating Bcl-2, MDR-1 and MRP-1. Int J Cancer 116: 155–160.
12. Chen Y, Wei X, Guo C, Jin H, Han Z, et al. (2010) Runx3 suppresses gastric
cancer metastasis through inactivation of MM9 by up-regulation of TIMP-1. Int
J Cancer.
13. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD (2000) RhoC GTPase,
a novel transforming oncogene for human mammary epithelial cells that
partially recapitulates the inflammatory breast cancer phenotype. Cancer Res
60: 5832–5838.
14. Liu N, Bi F, Pan Y, Sun L, Xue Y, et al. (2004) Reversal of the malignant
phenotype of gastric cancer cells by inhibition of RhoA expression and activity.
Clin Cancer Res 10: 6239–6247.
15. He L, Wang H, Jin H, Guo C, Xie H, et al. (2009) CIAPIN1 inhibits the growth
and proliferation of clear cell renal cell carcinoma. Cancer Lett 276: 88–94.
16. Meng Y, He L, Guo X, Tang S, Zhao X, et al. (2010) Gankyrin promotes the
proliferation of human pancreatic cancer. Cancer Lett 297: 9–17.
17. Xue Y, Bi F, Zhang X, Pan Y, Liu N, et al. (2004) Inhibition of endothelial cell
proliferation by targeting Rac1 GTPase with small interference RNA in tumor
cells. Biochem Biophys Res Commun 320: 1309–1315.
18. Pan Y, Zhao L, Liang J, Liu J, Shi Y, et al. (2006) Cellular prion protein
promotes invasion and metastasis of gastric cancer. FASEB J 20: 1886–1888.
19. Peng Z, Tang H, Wang X, Zhou C, Fan J, et al. (2008) Inhibition of the growth
and metastasis of human colon cancer by restoration of RUNX3 expression in
cancer cells. Int J Oncol 33: 979–984.
20. Tsunematsu T, Kudo Y, Iizuka S, Ogawa I, Fujita T, et al. (2009) RUNX3 has
an oncogenic role in head and neck cancer. PLoS One 4: e5892.
21. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:
323–330.
22. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677.
23. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing
paradigm. Nat Rev Cancer 9: 153–166.
24. Mithani SK, Balch GC, Shiou SR, Whitehead RH, Datta PK, et al. (2004)
Smad3 has a critical role in TGF-beta-mediated growth inhibition and apoptosis
in colonic epithelial cells. J Surg Res 117: 296–305.
25. Malumbres M, Barbacid M (2006) Is Cyclin D1-CDK4 kinase a bona fide
cancer target? Cancer Cell 9: 2–4.
26. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a
nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812–821.
27. Li W, Kotoshiba S, Berthet C, Hilton MB, Kaldis P (2009) Rb/Cdk2/Cdk4
triple mutant mice elicit an alternative mechanism for regulation of the G1/S
transition. Proc Natl Acad Sci U S A 106: 486–491.
28. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of
G1-phase progression. Genes Dev 13: 1501–1512.
29. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, et al. (1997) High level of
urokinase-type plasminogen activator is a new prognostic marker in patients with
gastric carcinoma. Cancer 79: 878–883.
30. Jin H, Pan Y, He L, Zhai H, Li X, et al. (2007) p75 neurotrophin receptor
inhibits invasion and metastasis of gastric cancer. Mol Cancer Res 5: 423–433.
31. Okamoto T, Niu R, Yamada S (2003) Increased expression of tissue inhibitor of
metalloproteinase-2 in clear cell carcinoma of the ovary. Mol Hum Reprod 9:
569–575.
RUNX3 Suppresses Growth and Metastasis of CCRCC
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32961